Invivyd (NASDAQ:IVVD) Stock

INVIVYD INC

Invivyd

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Invivyd Inc

Needham analyst Joseph Stringer maintains Inozyme Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INZY#NASDAQ">INZY</a>) with a Buy and lowers the price target from $15 to $12.

News

Price Target

Analyst Ratings

INZY

Needham Maintains Buy on Inozyme Pharma, Lowers Price Target to $12

Wall Street analysts rerated JD.com, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) on Wednesday, including slashing their price targets after the company reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45385027/jd-com-clocks-strong-q1-retail-and-logistics-growth-fueled-by-cash-burn" rel="noreferrer noopener">first-quarter results</a> on Tuesday.
The stock is trading lower on Wednesday.
Benchmark analyst Fawne Jiang maintained JD.com with a Buy and lowered the <a href="https://www.benzinga.com/quote/JD/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $58 to $53</a>.
Also Read: <a href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs" target="_blank" rel="noreferrer noopener">US Listed Chinese Stocks Rally As Countries Agree To Ease Import Tariffs</a>
Jiang noted that net revenue was 301 billion Chinese yuan (+15.8%) or $41.5 billion, beating consensus expectations by 11 billion Chinese yuan.
Notably, thanks to the trade-in program, growth of 3C and home appliances accelerated to 17% while gross margin also accelerated to 15% growth (versus 11% prior), thanks to improvements in user growth and engagement, with supermarkets continuing to outperform at double-digit growth, the analyst said.&nbsp;&nbsp;
Adjusted EPADS came in at 8.41 Chinese yuan (or $1.16), beating consensus by $0.19.
He added that the company had repurchased $1.5 billion in shares year-to-date, reducing its share count by 2.8%.
Management highlighted continued policy tailwinds and improving organic growth year-to-date. With improving consumer sentiment and ongoing enhancements to its ecosystem, the company raised its fiscal 2025 retail growth outlook to double-digit growth (versus high-single-digit prior).&nbsp;&nbsp;
Management noted sustained momentum in the second quarter. General merchandise categories exhibited solid growth, bolstered by supermarket and fashion categories.&nbsp;&nbsp;
While the comparison will be tough heading into fiscal 2026, Jiang is encouraged by the momentum in gross margin, the focus on the 3P marketplace, and the planned revamp of key categories (such as fashion). According to the analyst, these factors will drive sustainable long-term growth.
In the first quarter, JD also entered the food delivery market and achieved impressive traction, with daily orders approaching 20 million within three months. While Jiang noted the move as strategic and saw significant potential in food delivery and the broader on-demand retail ecosystem, the investment introduces margin uncertainty for the remainder of the year, if not longer. 
Given the need to dynamically adjust promotional strategies, expansion plans, and monetization pace in response to a fluid macroeconomic and competitive environment, JD withdrew its fiscal 2025 group-level profitability guidance, citing limited visibility and ongoing market volatility. Based on the current subsidy levels and cost structure, the analyst estimated increased pressure on margins and revised his earnings forecasts accordingly.
Jiang raised his fiscal 2025 and 2026 revenue estimates to 1.290 trillion Chinese yuan (+11.6%) and 1.342 trillion Chinese yuan (+3.8%), respectively. However, the analyst lowered his adjusted adjusted EPADS estimates to $4.61 for fiscal 2025 and $4.95 for fiscal 2026.
Price Action: JD stock is up 4% at $35.74 at last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45377667/tencent-music-q1-paying-user-growth-more-than-offsets-monthly-active-user-loss" target="_blank" rel="noreferrer noopener">Tencent Music Q1 Paying User Growth More Than Offsets Monthly Active User Loss</a></li>
</ul>
Photo: Shutterstock

Reiteration

Trading Ideas

JD.com Gains Traction In Retail, Delivery As Analyst Flags Margin Risks

ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-15. Here's what investors need to know before the announcement.
Analysts estimate that ESS Tech will report an earnings per share (EPS) of $-1.23. 
The market awaits ESS Tech's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.66 in the last quarter, leading to a 12.58% drop in the share price on the following day.
Here's a look at ESS Tech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.31</td>
<td>-1.26</td>
<td>-0.10</td>
<td>-0.11</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.97</td>
<td>-1.90</td>
<td>-0.12</td>
<td>-0.10</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-13.0%</td>
<td>-18.0%</td>
<td>-13.0%</td>
<td>-15.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747246352_0.png" alt="eps graph" />
<h3>Market Performance of ESS Tech's Stock</h3>
Shares of ESS Tech were trading at $2.8 as of May 13. Over the last 52-week period, shares are down 75.28%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/GWH/earnings">To track all earnings releases for ESS Tech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Insights into ESS Tech's Upcoming Earnings

<a href="https://www.bloomberg.com/news/articles/2025-05-14/coinbase-s-armstrong-looks-to-make-more-acquisitions-after-deribit-purchase">https://www.bloomberg.com/news/articles/2025-05-14/coinbase-s-armstrong-looks-to-make-more-acquisitions-after-deribit-purchase</a>

General

COIN

'Coinbase's Armstrong Looks to Make More Acquisitions After Deribit Purchase'- Bloomberg

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and maintains $3 price target.

LUCD

Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target

<a href="https://bofa.veracast.com/webcasts/bofa/transportationairlines2025/idoV6dju.cfm">https://bofa.veracast.com/webcasts/bofa/transportationairlines2025/idoV6dju.cfm</a>

Lockheed Martin CFO During Conference Call Reportedly Says We Still See Tariffs Not As A Cost Of Profit Risk For Us, But Potentially A Cash Timing Risk

Michael Saylor's Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) has engineered a financial mechanism that transforms market enthusiasm for Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) into a self-reinforcing growth engine, according to the <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45257429/michael-saylor-calls-bitcoin-the-corporate-survival-strategy-for-96-of-companies">company&#8217;s executive chairman</a>.
What Happened: In a Financial Times interview on May 13, Saylor <a href="https://www.youtube.com/watch?v=O_WjH0mqKww">detailed</a> the mechanics behind his Bitcoin-focused strategy, which he claims helped the firm outperform tech titans like NVIDIA and Meta en route to a $100 billion valuation.
Describing the system as a "quadratically reflexive, engineered instrument," Saylor openly embraces his role as a financial architect, one who, according to crypto enthusiasts, has created something akin to an "infinite money glitch."
How It Works: The strategy hinges on an arbitrage mechanism: when MicroStrategy&#8217;s stock trades at a premium to the value of its Bitcoin holdings, the company issues new shares to raise capital and buys more BTC, effectively acquiring the asset at a steep discount.
&#8220;If our stock trades at a 200% premium to the underlying asset, we can sell a billion dollars of the stock, buy back the underlying asset, and make $666 million in that arbitrage of sorts,&#8221; Saylor explained.
This dynamic allowed Strategy to raise capital at unprecedented speed. "During the November stock surge, they raised $12 billion in just 50 days," noted digital investor Jeff Walton. "Raising $100 million once is tough, they did it 120 times in 50 days."
Unlike most firms, where dilution frustrates investors, Strategy's shareholders embrace the model, as it increases the amount of Bitcoin held per share. 
The firm also used its premium to secure favorable debt deals, recently issuing $5 billion in convertible bonds at 0% interest.
Also Read: <a href="https://in.benzinga.com/markets/cryptocurrency/25/05/45375869/bitcoin-up-22-in-30-days-whats-driving-the-surge">Bitcoin Up 22% In 30 Days: What&#8217;s Driving The Surge?</a>
Why It Matters: The model functions like a self-reinforcing loop: capital is raised, Bitcoin is bought, Bitcoin price rises, the company's share price climbs, and the cycle repeats. 
Saylor's promotional push, including non-stop Bitcoin evangelism on social media and even hosting Bitcoin-themed parties at his Miami home, further fuels demand.
But the strategy is not without risk. 
It depends entirely on Bitcoin's continued ascent. In early 2025, when regulatory concerns triggered a BTC selloff, Strategy recorded nearly $6 billion in unrealized losses for Q1.
Though Bitcoin has since rebounded, critics argue the model is precarious, requiring constant new capital and strong market sentiment to remain sustainable.
What's Next: Despite volatility, Saylor remains unwaveringly bullish. 
He forecasts Bitcoin at $1 million within 10 years, and potentially $13 million by 2045. If that happens, he envisions Strategy scaling "from a $100 billion firm to a $1 trillion, even $10 trillion enterprise."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45415288/coinbase-ceo-brian-armstrong-invites-doge-staff-to-create-a-more-efficient-financial-syste">Coinbase CEO Brian Armstrong Invites DOGE Staff To &#8216;Create A More Efficient Financial System&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

Michael Saylor's Bitcoin Strategy—'Infinite Money Glitch' Or A Reflexive Leverage Bet?

Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) stocks gained on Wednesday after reports indicated the Trump Administration plans to&nbsp;repeal the Biden administration&#8217;s <a target="_blank" href="https://www.benzinga.com/topic/ai" rel="noreferrer noopener">artificial intelligence diffusion</a> that created three broad tiers of access for countries seeking AI chips and would have taken effect May 15.
President Trump&#8217;s administration has warned global companies against using Huawei Technologies Ascend AI chips, threatening them with criminal penalties for violating U.S. semiconductor sanctions, Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-05-13/trump-to-rewrite-ai-chip-curbs-reviled-by-nvidia-and-us-allies?sref=TBDibEcD" rel="noreferrer noopener">reported</a> on Wednesday, citing unnamed sources familiar with the matter.
Instead, the U.S. government is drafting its approach and could forge individual deals with countries.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45414265" rel="noreferrer noopener">Nvidia Climbs On Saudi AI Investments: Analyst Estimates $15 Billion To $20 Billion In Revenue</a>
Huawei has begun delivering AI chip &#8220;clusters&#8221; to clients in China, which it claims to outperform the leading U.S. AI chipmaker, Nvidia, on key metrics such as total computing and memory.
Huawei is boosting production capacity by building its advanced semiconductor production lines, as Chinese companies cut off from Nvidia&#8217;s products are increasing orders.
Reportedly, Trump&#8217;s government is still working on replacement regulations. Trump officials intend to impose curbs on countries that have diverted chips to China, including Malaysia and Thailand.
At the same time, the Commerce Department will continue to enforce existing chip export rules strictly.
The U.S. officially blacklisted Huawei in May 2019 (during President Trump&#8217;s first term), citing national security threats. The Biden administration launched multiple semiconductor sanctions on China, restricting its access to Nvidia and rival semiconductor technologies.
Meanwhile, President&nbsp;Trump&nbsp;<a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45390422/trump-unveils-historic-and-transformative-600-billion-saudi-deal-predicts-markets-will-go-a-lot-higher" rel="noreferrer noopener">showcased Saudi Arabia&#8217;s</a> $600 billion investment commitment in the U.S. on Tuesday, listing a series of multibillion-dollar deals with leading American corporations&nbsp;in tech, defense, and infrastructure.
The company announced multi-billion dollar commercial deals with&nbsp;companies including Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>),&nbsp;Oracle Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>),&nbsp;and AMD.
Price Actions: NVDA stock is up 3.81% at $134.86 at last check on Wednesday. AMD is up 4.06%.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45379380/can-corning-broadcom-deal-transform-ais-data-center-future" target="_blank" rel="noreferrer noopener">Can Corning-Broadcom Deal Transform AI&#8217;s Data Center Future?</a></li>
</ul>
Photo via Shutterstock

Government

Regulations

Movers

Tech

Media

AMZN

NVDA

ORCL

Nvidia, AMD And Other Chip Stocks Gain As Trump Plans To Ease AI Chip Export Rules

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth assumes Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy rating and announces Price Target of $4.

Initiation

HUMA

HC Wainwright & Co. Assumes Humacyte at Buy, Announces Price Target of $4

WIIM

RIVN

RIVN stock has given up its prior loss. Rivian Automotive shares were trading lower after Jefferies downgraded the stock from Buy to Hold.

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares are trading higher by more than 4% on Wednesday, extending its recent rally to approximately 24% over the past week and about 37% <a href="https://www.benzinga.com/25/05/45376757/tesla-back-in-the-trillionaire-club-tsla-stock-roars-back-with-40-rebound-robotaxi-mania">over the past month</a>.
The surge follows easing U.S.-China trade tensions and renewed investor optimism around Tesla's robotaxi rollout and next-generation vehicle production.
What To Know: Tesla is reportedly <a href="https://www.benzinga.com/tech/25/05/45401165/tesla-gears-up-to-restart-key-component-shipping-from-china-for-cybercab-semi-truck-production-in-us-report">preparing</a> to resume shipping components from China to the U.S. for its upcoming Cybercab and Semi models after the Trump administration rolled back tariffs.
The <a href="https://www.benzinga.com/government/regulations/25/05/45358876/dow-jones-adds-1000-points-breaks-200-day-moving-average">truce</a>, announced Monday, enables Tesla to restart production plans that had stalled due to 145% import duties. Trial production of the Cybercab is expected to begin in Texas by October, with the Semi set to be built in Nevada.
Read Also: <a href="https://www.benzinga.com/news/25/05/45412770/oklo-stock-jumps-on-new-cto-improved-q1-and-nuclear-plant-progress">Oklo Stock Jumps On New CTO, Improved Q1 And Nuclear Plant Progress</a>
Wedbush analyst Dan Ives has named Tesla a &#8220;huge beneficiary&#8221; of the U.S.-China de-escalation, adding that Musk&#8217;s <a href="https://www.benzinga.com/tech/25/05/45357613/china-tariff-de-escalation-biggest-winners-include-tesla-apple-new-tech-highs-back-on-the-table-now-for-2025" target="_blank" rel="noreferrer noopener">renewed focus</a>, after months in a controversial White House role, marks a &#8220;pivotal moment&#8221; for the company.
Ives on Wednesday also pointed to the U.S.-Saudi Investment Forum in Riyadh, calling it a &#8220;bullish eye-opener&#8221; for investors in U.S. tech stocks, including Tesla. 
&#8220;The AI Revolution is coming to the Saudi Kingdom and Riyadh will be a major buyer of AI chips, software, autonomous/robotics, datacenters over the next decade,&#8221; Ives said in an X <a href="https://x.com/DivesTech/status/1922626073335914520">post</a>. 
What Else: Meanwhile, Tesla faces <a href="https://www.benzinga.com/markets/equities/25/05/45402695/teslas-robotaxi-plans-under-federal-scrutiny-ahead-ff-austin-launch-as-elon-musk-vows-nationwide-rollout-by-year-end">federal scrutiny</a> ahead of its planned June robotaxi launch in Austin. The National Highway Traffic Safety Administration is seeking details on how Tesla's autonomous vehicles will operate in low-visibility conditions like fog and rain — issues linked to past accidents. Despite this, CEO Elon Musk remains confident, <a href="https://www.benzinga.com/markets/equities/25/05/45402695/teslas-robotaxi-plans-under-federal-scrutiny-ahead-ff-austin-launch-as-elon-musk-vows-nationwide-rollout-by-year-end">projecting</a> "millions of robotaxis" nationwide by year-end.
The Cybercab and robotaxi initiatives have been central to Tesla's growth narrative, especially as the company rebounds from a <a href="https://www.benzinga.com/news/earnings/25/04/44937440/tesla-q1-misses-estimates-as-tariff-pressures-weigh-on-outlook-lower-cost-evs-still-on-track">weak first quarter</a>.
Read Also: <a href="https://www.benzinga.com/government/regulations/25/05/45414023/magnificent-seven-add-36-trillion-since-april-lows-is-this-rally-just-beginning">Magnificent Seven Add $3.6 Trillion Since April Lows: Is This Rally Just Beginning?</a>
<h2 class="wp-block-heading">How To Buy TSLA Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Tesla&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, TSLA has a 52-week high of $488.54 and a 52-week low of $157.40. Tesla shares were up 4.07% at $347.66 at the time of publication Wednesday.

TSLA

Tesla Stock Continues To Climb: What's Going On?

Whales with a lot of money to spend have taken a noticeably bullish stance on Axon Enterprise.
Looking at options history for Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 44% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $468,925 and 6, calls, for a total amount of $486,184.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $450.0 and $900.0 for Axon Enterprise, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Axon Enterprise's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Axon Enterprise's whale activity within a strike price range from $450.0 to $900.0 in the last 30 days. 
<h3>Axon Enterprise 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747245683_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$17.7</td>
<td>$17.6</td>
<td>$17.6</td>
<td>$690.00</td>
<td>$297.4K</td>
<td align="right">77</td>
<td align="right">154</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$83.2</td>
<td>$77.3</td>
<td>$83.2</td>
<td>$900.00</td>
<td>$249.6K</td>
<td align="right">2</td>
<td align="right">30</td>
</tr>
<tr>
<td>AXON</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$17.5</td>
<td>$16.4</td>
<td>$17.5</td>
<td>$690.00</td>
<td>$126.6K</td>
<td align="right">77</td>
<td align="right">72</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$44.2</td>
<td>$40.2</td>
<td>$42.99</td>
<td>$700.00</td>
<td>$65.3K</td>
<td align="right">289</td>
<td align="right">32</td>
</tr>
<tr>
<td>AXON</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$51.3</td>
<td>$44.3</td>
<td>$46.0</td>
<td>$700.00</td>
<td>$59.8K</td>
<td align="right">289</td>
<td align="right">15</td>
</tr>
</tbody>
</table>

<h3>About Axon Enterprise</h3>
Axon Enterprise Inc is building a public safety operating system by integrating a suite of hardware devices and cloud software solutions. The company's suite includes cloud-hosted digital evidence management solutions, productivity and real-time operations software, body cameras, in-car cameras, TASER energy devices, drones and robotic security, and training solutions. The company's operation comprises of two operating segments, Software and Sensors, and TASER. The company generates the majority of its revenue from the Software and Sensors segment, which is engaged in developing, manufacturing, and selling fully integrated hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Having examined the options trading patterns of Axon Enterprise, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Axon Enterprise Standing Right Now?</h3>
<ul>
<li>With a trading volume of 319,925, the price of AXON is up by 0.31%, reaching $726.99.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 83 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Axon Enterprise</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $728.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Axon Enterprise with a target price of $830. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for Axon Enterprise, targeting a price of $750. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $600. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on Axon Enterprise, which currently sits at a price target of $735. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Axon Enterprise with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Markets

AXON

Check Out What Whales Are Doing With AXON

Whales with a lot of money to spend have taken a noticeably bearish stance on DoorDash.
Looking at options history for DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 66% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $2,100,358 and 2, calls, for a total amount of $60,260.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $180.0 to $220.0 for DoorDash over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in DoorDash's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to DoorDash's substantial trades, within a strike price spectrum from $180.0 to $220.0 over the preceding 30 days.
<h3>DoorDash Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747245677_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DASH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$6.35</td>
<td>$6.25</td>
<td>$6.35</td>
<td>$185.00</td>
<td>$876.9K</td>
<td align="right">68</td>
<td>1.7K</td>
</tr>
<tr>
<td>DASH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.95</td>
<td>$3.85</td>
<td>$3.95</td>
<td>$185.00</td>
<td>$695.9K</td>
<td align="right">887</td>
<td>1.7K</td>
</tr>
<tr>
<td>DASH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$6.35</td>
<td>$6.3</td>
<td>$6.35</td>
<td>$185.00</td>
<td>$257.8K</td>
<td align="right">68</td>
<td>406</td>
</tr>
<tr>
<td>DASH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$3.95</td>
<td>$185.00</td>
<td>$76.2K</td>
<td align="right">887</td>
<td>1.9K</td>
</tr>
<tr>
<td>DASH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/20/26</td>
<td>$39.2</td>
<td>$38.4</td>
<td>$38.67</td>
<td>$220.00</td>
<td>$58.0K</td>
<td align="right">24</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About DoorDash</h3>
Founded in 2013 and headquartered in San Francisco, DoorDash is an online delivery demand aggregator. Consumers can use its app to order food items on-demand for delivery or in-store from merchants. Through the acquisition of Wolt in 2022, the firm also provides this service in Europe and Asia. DoorDash creates a marketplace for merchants to establish a presence online, market their offerings, and meet demand through delivery. The firm provides similar service to nonrestaurant businesses, such as grocery, retail, and pet supplies. Dash is also rolling out nascent technology like drone delivery in an effort to continually innovate and provide the best possible service to supply-side and demand-side contingents of its marketplace.
Following our analysis of the options activities associated with DoorDash, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of DoorDash</h3>
<ul>
<li>With a volume of 1,723,479, the price of DASH is down -0.49% at $196.84. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 78 days.</li>
</ul>
<h3>What Analysts Are Saying About DoorDash</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $211.6.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Needham continues to hold a Buy rating for DoorDash, targeting a price of $230. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $230. 
&#x2A; Consistent in their evaluation, an analyst from DA Davidson keeps a Neutral rating on DoorDash with a target price of $190. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Equal-Weight rating on DoorDash with a target price of $198. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $210. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DoorDash options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

DASH

Spotlight on DoorDash: Analyzing the Surge in Options Activity

Investors with a lot of money to spend have taken a bullish stance on Super Micro Computer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with SMCI, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 129 uncommon options trades for Super Micro Computer.
This isn't normal.
The overall sentiment of these big-money traders is split between 47% bullish and 44%, bearish.
Out of all of the special options we uncovered, 29 are puts, for a total amount of $2,281,957, and 100 are calls, for a total amount of $8,237,454.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $115.0 for Super Micro Computer, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Super Micro Computer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Super Micro Computer's substantial trades, within a strike price spectrum from $3.0 to $115.0 over the preceding 30 days.
<h3>Super Micro Computer Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747245671_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$8.35</td>
<td>$8.2</td>
<td>$8.31</td>
<td>$40.00</td>
<td>$599.9K</td>
<td>9.4K</td>
<td>934</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/18/26</td>
<td>$14.2</td>
<td>$13.85</td>
<td>$14.0</td>
<td>$62.00</td>
<td>$280.0K</td>
<td>1.1K</td>
<td>255</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$0.98</td>
<td>$0.91</td>
<td>$0.91</td>
<td>$33.00</td>
<td>$131.4K</td>
<td>2.8K</td>
<td>3.4K</td>
</tr>
<tr>
<td>SMCI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/20/26</td>
<td>$15.1</td>
<td>$14.95</td>
<td>$15.0</td>
<td>$42.00</td>
<td>$117.0K</td>
<td>574</td>
<td>287</td>
</tr>
<tr>
<td>SMCI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$14.5</td>
<td>$14.25</td>
<td>$14.5</td>
<td>$50.00</td>
<td>$110.2K</td>
<td>6.2K</td>
<td>258</td>
</tr>
</tbody>
</table>

<h3>About Super Micro Computer</h3>
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, Big Data, high-performance computing, and the "Internet of Things" embedded markets. Its solutions include server, storage, blade, and workstations to full racks, networking devices, and server management software. The firm follows a modular architectural approach, which provides flexibility to deliver customized solutions. The Company operates in one operating segment that develops and provides high-performance server solutions based upon an innovative, modular, and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
<h3>Super Micro Computer's Current Market Status</h3>
<ul>
<li>Trading volume stands at 132,695,179, with SMCI's price up by 17.1%, positioned at $45.54.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>What The Experts Say On Super Micro Computer</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $40.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Super Micro Computer, targeting a price of $34. 
&#x2A; An analyst from Citigroup has decided to maintain their Neutral rating on Super Micro Computer, which currently sits at a price target of $37. 
&#x2A; An analyst from Rosenblatt persists with their Buy rating on Super Micro Computer, maintaining a target price of $55. 
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $39. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $39.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Super Micro Computer options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

SMCI

Spotlight on Super Micro Computer: Analyzing the Surge in Options Activity

In the preceding three months, 4 analysts have released ratings for Eton Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETON#NASDAQ">ETON</a>), presenting a wide array of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.75, with a high estimate of $33.00 and a low estimate of $24.00. This upward trend is evident, with the current average reflecting a 7.77% increase from the previous average price target of $25.75.
<img src="https://www.benzinga.com/files/images/story/2025/1747245665_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Eton Pharmaceuticals among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chase Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Chase Knickerbocker</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$26.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Madison El-Saadi</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$24.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$33.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Eton Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eton Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Eton Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Eton Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ETON/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Eton Pharmaceuticals analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Eton Pharmaceuticals</h2>
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
<h3>Unraveling the Financial Story of Eton Pharmaceuticals</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Eton Pharmaceuticals displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 59.26%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Eton Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -5.13% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Eton Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.96% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Eton Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -1.07%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.22, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ETON

A Glimpse Into The Expert Outlook On Eton Pharmaceuticals Through 4 Analysts

Ratings for Helmerich &amp; Payne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $25.86, a high estimate of $32.00, and a low estimate of $20.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 22.41%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747245653_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A comprehensive examination of how financial experts perceive Helmerich &amp; Payne is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$28.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$25.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Scott Gruber</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$32.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Daniel Kutz</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Underweight</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Helmerich &amp; Payne. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Helmerich &amp; Payne compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Helmerich &amp; Payne's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Helmerich &amp; Payne's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/HP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Helmerich &amp; Payne analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Helmerich &amp; Payne's Background</h2>
Helmerich &amp; Payne Inc provides performance-driven drilling solutions and technologies that are intended to make hydrocarbon recovery safer and more economical for oil and gas exploration and production companies. The Company focus on the drilling segment of the oil and gas production value chain. Company operates in North America, Gulf of Mexico, and other international places such as Argentina, Australia, Bahrain, Colombia and the United Arab Emirates (UAE). Also own and operates a limited number of commercial real estate properties located in Tulsa, Oklahoma. It's real estate investments include a shopping center and of undeveloped real estate projects.
<h3>Financial Insights: Helmerich &amp; Payne</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Helmerich &amp; Payne displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 50.01%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Energy sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Helmerich &amp; Payne's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 0.16%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Helmerich &amp; Payne's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 0.06%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Helmerich &amp; Payne's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.03%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.76.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Helmerich & Payne Stock

In the current session, Portland Gen Electric Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) is trading at $41.17, after a 0.80% decrease. Over the past month, the stock decreased by 4.88%, and in the past year, by 9.65%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1747245654_0.png" alt="Past Year Chart" />

<h3>Portland Gen Electric P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Portland Gen Electric has a lower P/E than the aggregate P/E of 16.78 of the Electric Utilities industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747245654_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Portland Gen Electric

Throughout the last three months, 10 analysts have evaluated Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $45.7, a high estimate of $52.00, and a low estimate of $39.00. This current average has decreased by 2.31% from the previous average price target of $46.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1747245647_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Freeport-McMoRan by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Orest Wowkodaw</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$43.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Chris LaFemina</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Timna Tanners</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$39.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Major</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Orest Wowkodaw</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brian MacArthur</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Abhi Agarwal</td>
<td>Deutsche Bank</td>
<td>Maintains</td>
<td>Buy</td>
<td>$47.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Chris LaFemina</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$48.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Freeport-McMoRan. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Freeport-McMoRan compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Freeport-McMoRan's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Freeport-McMoRan's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FCX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Freeport-McMoRan analyst ratings.</a>
<h2>All You Need to Know About Freeport-McMoRan</h2>
Freeport-McMoRan owns stakes in 10 copper mines, led by its 49% ownership of the Grasberg copper and gold operations in Indonesia, 55% of the Cerro Verde mine in Peru, and 72% of Morenci in Arizona. It sold around 1.2 million metric tons of copper (its share) in 2024, making it the one of the world's largest copper miners by volume. It also sold about 900,000 ounces of gold, mostly from Grasberg, and 70 million pounds of molybdenum. It had about 25 years of copper reserves at the end of December 2024. We expect it to sell similar amounts of copper midcycle in 2029, though we expect gold volumes to decline to about 700,000 ounces then due to falling production at Grasberg.
<h3>Freeport-McMoRan: Financial Performance Dissected</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Decline in Revenue: Over the 3M period, Freeport-McMoRan faced challenges, resulting in a decline of approximately -9.38% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Freeport-McMoRan's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 6.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Freeport-McMoRan's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.0%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Freeport-McMoRan's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.64%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Freeport-McMoRan's debt-to-equity ratio surpasses industry norms, standing at 0.53. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Have This To Say About Freeport-McMoRan

6 analysts have shared their evaluations of Zevra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVRA#NASDAQ">ZVRA</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Zevra Therapeutics, presenting an average target of $22.5, a high estimate of $25.00, and a low estimate of $18.00. This current average reflects an increase of 3.83% from the previous average price target of $21.67. 
<img src="https://www.benzinga.com/files/images/story/2025/1747245637_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Zevra Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Eddie Hickman</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$22.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jason Butler</td>
<td>Citizens Capital Markets</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Zevra Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zevra Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Zevra Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZVRA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Zevra Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Zevra Therapeutics Better</h2>
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
<h3>Zevra Therapeutics: Financial Performance Dissected</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Zevra Therapeutics's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -6.79%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Zevra Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -296.76%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Zevra Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -65.31%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -19.34%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Zevra Therapeutics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.52, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZVRA

Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views

GoDaddy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) short percent of float has fallen 31.42% since its last report. The company recently reported that it has 2.90 million shares sold short, which is 2.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.13 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>GoDaddy Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747245632_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for GoDaddy has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing GoDaddy's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, GoDaddy's peer group average for short interest as a percentage of float is 7.05%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

GDDY

What Does the Market Think About GoDaddy?

Press Releases

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Health Care

FDA Declined Invivyd's Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Management

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Financing

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

Invivyd Announces New Pipeline Discovery Program Focused on Monoclonal Antibody Treatment for Measles

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Comments

Invivyd

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL